Microbot Medical (FRA:CY9D) EBIT: €-13.79 Mil (TTM As of Mar. 2026)

What is Microbot Medical EBIT?

Microbot Medical FRA:CY9D +4.89% 33 EBIT is €-13.79 Mil as of Mar. 2026. GuruFocus rates FRA:CY9D with a GF Score™ of 33/100. The stock has 2 warning signs investors should review.

Microbot Medical's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was €-3.74 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was €-13.79 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Microbot Medical's annualized ROC % for the quarter that ended in Mar. 2026 was -527.82%. Microbot Medical's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -1,176.54%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Microbot Medical's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -26.45%.

Microbot Medical (FRA:CY9D) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Microbot Medical's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

	ROC % (Q: Mar. 2026 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Dec. 2025 )	+	Invested Capital (Q: Mar. 2026 ))	/ count )
=	-14.948 * ( 1 - 0% )	/	( (3.498	+	2.166)	/ 2 )
=	-14.948	/	2.832
=	-527.82 %

where

	Invested Capital		(Q: Dec. 2025 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	69.639	-	0.895	-	( 67.118	-	max(0, 2.922	-	68.168	+	67.118	))
=	3.498

	Invested Capital		(Q: Mar. 2026 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	67.527	-	2.649	-	( 62.712	-	max(0, 2.93	-	66.197	+	62.712	))
=	2.166

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Microbot Medical's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Mar. 2026 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Dec. 2025		Q: Mar. 2026
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-14.948	/	( ( (0.791 + max(-2.169, 0))	+	(0.915 + max(0.83499999999999, 0)) )	/	2 )
=	-14.948	/	( ( 0.791	+	1.75 )	/	2 )
=	-14.948	/	1.2705
=	-1,176.54 %

where Working Capital is:

	Working Capital		(Q: Dec. 2025 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0.499	+	0.0010000000000048)	-	(0.895	+	0.079	+	1.695)
=	-2.169

	Working Capital		(Q: Mar. 2026 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0.091	+	1.952	+	1.442)	-	(2.649	+	0	+	0.00099999999999989)
=	0.83499999999999

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Microbot Medical's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Mar. 2026 )
	=	-13.789	/	52.133
	=	-26.45 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Microbot Medical EBIT Related Terms

Microbot Medical EBIT Historical Data

* Premium members only.

The historical data trend for Microbot Medical's EBIT can be seen below:

Microbot Medical EBIT Chart

Microbot Medical Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

EBIT

Get a 7-Day Free Trial

-10.05

-12.69

-9.30

-11.10

-12.59

Microbot Medical Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
EBIT	Get a 7-Day Free Trial															-2.79	-3.23	-3.29	-3.53	-3.74

FRA:CY9D vs STXS, POCI, DXR: EBIT Comparison

For the Medical Instruments & Supplies subindustry, Microbot Medical's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Microbot Medical EV-to-EBIT vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Microbot Medical's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Microbot Medical's EV-to-EBIT falls into.

Save Embed

33GF Score

Microbot Medical Inc FRA:CY9D

EBIT is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Microbot Medical EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-13.79 Mil.

Frequently Asked Questions Learn more about EBIT →

What does a EBIT of €-13.79 Mil mean?

Microbot Medical (FRA:CY9D) has a EBIT of €-13.79 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Microbot Medical.

Is Microbot Medical's EBIT too high?

Microbot Medical's current EBIT is €-13.79 Mil. Overall, Microbot Medical has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.

How does Microbot Medical's EBIT compare to STXS and POCI?

Microbot Medical's EBIT of €-13.79 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good EBIT for a Medical Devices & Instruments company?

A good EBIT depends on the Medical Devices & Instruments industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high EBIT mean?

A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Microbot Medical. Microbot Medical's current EBIT is €-13.79 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Microbot Medical stock overvalued right now?

Microbot Medical (FRA:CY9D) has a current EBIT of €-13.79 Mil. The current EBIT is €-13.79 Mil. Microbot Medical's overall GF Score™ is 33/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is EBIT calculated?

EBIT is calculated from a company's financial statements. For Microbot Medical (FRA:CY9D), the current EBIT is €-13.79 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Microbot Medical Business Description

Industry Healthcare Medical Devices & Instruments

Comparable Companies STXS POCI DXR PDEX NEPH KRMD EMBC MLSS RGNT HBIO ISRG XPAR:EL TSE:7741 BDX XSWX:ALC MDLN RMD WST XSWX:STMN TSE:4543

Other Exchanges MBOT:USA

Address 175 Derby Street, Building 27, Hingham, MA, USA, 02043

Website https://www.microbotmedical.com

Microbot Medical Inc is a medical device company specializing in the research, design, and development of next-generation robotic endoluminal surgery devices targeting the minimally invasive surgery space. Using its LIBERTY technological platform, the company has developed the LIBERTY Endovascular Robotic Surgical System, a fully disposable robot for various endovascular interventional procedures. The company has a single operating and reportable segment, which is the development of robotic devices for endoluminal surgery.

33GF Score

Get the complete analysis for FRA:CY9D

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.61

Price

View FRA:CY9D Analysis

See EBIT data for all stocks →